[1]王 碧,吉茂礼.乳腺癌组织长链非编码RNA UCA1和BCAR4表达与辅助化疗效果的相关性研究[J].现代检验医学杂志,2019,34(05):77-80.[doi:10.3969/j.issn.1671-7414.2019.05.019]
　WANG Bi,JI Mao-li.Correlational Research on the Expressionof Long-Chain Non-Coding RNA UCA1 and BCAR4in Breast Cancer Tissues for the Effect of Adjuvant Chemotherapy[J].Journal of Modern Laboratory Medicine,2019,34(05):77-80.[doi:10.3969/j.issn.1671-7414.2019.05.019]
点击复制

乳腺癌组织长链非编码RNA UCA1和BCAR4表达与辅助化疗效果的相关性研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第34卷
期数:
2019年05期
页码:
77-80
栏目:
论著
出版日期:
2019-10-29

文章信息/Info

Title:
Correlational Research on the Expressionof Long-Chain Non-Coding RNA UCA1 and BCAR4in Breast Cancer Tissues for the Effect of Adjuvant Chemotherapy
文章编号:
1671-7414(2019)05-077-04
作者:
王 碧1; 吉茂礼2
(1.陕西省核工业二一五医院检验科,陕西咸阳 712000; 2.商洛市中心医院检验科,陕西商洛 726000)
Author(s):
WANG Bi1; JI Mao-li2
(1.Department of Clinical Laboratory,215 Hospital of Nuclear Industry of Shaanxi Province,Shaanxi Xianyang 712000,China; 2.Department of Clinical Laboratory, the Central Hospital of Shangluo City of Shaanxi Province,Shaanxi Shangluo 726000,China)
关键词:
乳腺癌;  辅助化疗;  有效;  无效;  长链非编码RNA;  尿路上皮癌相关1(UCA1);  乳腺癌雌激素耐受基因4(BCAR4);  糖类抗原153(CA153)
分类号:
R737.9; R730.43
DOI:
10.3969/j.issn.1671-7414.2019.05.019
文献标志码:
A
摘要:
目的 探讨乳腺癌组织长链非编码RNA(long non-codingRNA,lncRNA)尿路上皮癌相关1(urothelial carcinoma-associated 1,UCA1)和乳腺癌雌激素耐受基因4(breast cancer anti-estrogen resistance 4,BCAR4)表达与辅助化疗效果的相关性。方法 回顾性分析2016年12月～2018年12月在陕西省核工业二一五医院和陕西省商洛市中心医院接受辅助化疗的30例局部晚期乳腺癌患者的临床资料,依据化疗效果分为有效组(20例)和无效组(10例)。应用实时逆转录-聚合酶链反应(real-time reverse transcription-polymerase chain reaction,RT-PCR)技术检测乳腺癌组织lncRNA UCA1和BCAR4的表达,采用电化学发光技术检测血清糖类抗原(carbohydrate antigen,CA)153水平,比较分析以上指标的变化与乳腺癌辅助化疗效果的相关性。结果 在有效组和无效组中,UCA1和BCAR4的表达分别为0.37±0.15,0.91±0.26,0.41±0.17和0.96±0.29; 两标志物的异常率分别为23.3%,66.6%,20.0%和70.0%。在有效组和无效组中,血清CA153的水平分别为22.7±15.9,57.2±23.2 ng/ml,其异常率分别为(13.3%和46.6%)。与无效组比较,有效组组织UCA1,BCAR4表达和血清CA153水平显著降低,有效组三标志物的异常率也显著降低。以上比较的差异均有统计学意义(t=23.73～31.67,χ2=15.39～17.39,均P<0.01)。乳腺癌患者辅助化疗的有效率为66.6%,在乳腺癌辅助化疗无效组中,组织UCA1和BCAR4表达呈正相关性(r=0.839,P<0.01)。两标志物分别与血清CA153水平有正相关性(r=0.817～0.832,均P<0.01)。组织UCA1表达与乳腺癌患者的年龄无明显相关(χ2=1.148,P>0.05),而与肿瘤组织学分级和淋巴结转移具有相关性(χ2=7.500～8.103,均P<0.05)。BCAR4表达与乳腺癌患者的年龄和肿瘤组织学分级无相关性(χ2=1.200～1.975,均P>0.05),而与乳腺癌的淋巴结转移有相关性(χ2=6.531,P<0.05)。结论 UCA1和BCAR4与乳腺癌辅助化疗的耐药机制有关,下调UCA1和BCAR4表达可以促进辅助化疗的效果并有效缓解肿瘤的进展。
Abstract:
Objective To investigate the correlation on theexpression of long non-coding RNA(lncRNA)Urothelial carcinoma-associated 1(UCA1)and breast cancer anti-estrogen resistance 4(BCAR4)gene in breast cancertissues for the effect of adjuvant chemotherapy.Methods The clinical data of 30 patients with locally advanced breast cancer who received neoadjuvant chemotherapy in 215 Hospital of Nuclear Industry and the Central Hospital of Shangluo City of Shaanxi Province from December 2016 to December2018 were retrospectively analyzed.According to the effect of chemotherapy,they were divided into effective group(20 cases)and ineffective group(10 cases).Real-time reverse transcription-polymerase chain reaction(RT-PCR)was usedto detect the expression of long non-coding RNA(lncRNA)UCA1 and BCAR4 in tissues.The serum carbohydrate antigen(CA)153 level was detected by electrochemiluminescence technique.The correlation between the changes of the above indexesand the efficacy of adjuvant chemotherapy for breast cancer was compared and analyzed.Results In the effective group and the ineffective group,the expressions of UCA1 and BCAR4 were 0.37±0.15,0.91±0.26 and0.41±0.17,0.96±0.29,respectively,and their abnormal rates were 23.3%,66.6% and 20.0%,70.0%,respectively.The serum levels of CA153 in the effective group and the ineffective group was 22.7±15.9 and 57.2±23.2 ng/ml,and its abnormal rate was 13.3% and 46.6%,respectively.The expressions and abnormal rates of UCA1,BCAR4 and CA153 in the effective group were significantlylower than those in the ineffective group,and the differences were statistically significant(t=23.73～31.67,χ2=15.39～17.39,all P<0.01).Theoverall effective rate of adjuvant chemotherapy for breast cancer patients was66.6%.In the effective group of adjuvant chemotherapy for breast cancer,the expression of UCA1 and BCAR4 was positively correlated(r=0.839,P<0.01).The two markers were positively correlated with serum CA153 level(r=0.817～0.832,P<0.01).There was no significant correlation between UCA1 expressionand age of breast cancer patients(χ2=1.148,P>0.05),but significant correlation with histological grade and lymph node metastasis(χ2=7.500～8.103,all P<0.05).The expression of BCAR4 was not correlated with age and histological grade of breast cancer(χ2=1.200～1.975,all P>0.05),but was correlated with lymph node metastasis of breast cancer(χ2=6.531,P<0.05).Conclusion UCA1 and BCAR4 were related tothe drug resistance mechanism of adjuvant chemotherapy in breast cancer.Downregulation of UCA1 and BCAR4 expression can promote the effect of adjuvant chemotherapy and effectively alleviate the progress of cancer.

参考文献/References:

[1] VAN AGTHOVEN T,DORSSERS L C,LEHMA-NN U,et al.Breast cancer anti-estrogen resistance 4(BCAR4)drives proliferation of IPH-926 lobular carcinoma cells[J].PLoS One,2015,10(8):e0136845. [2] HAYES E L,LEWIS-WAMBI J S.Mechanisms of endocrine resistance in breastcancer:an overview of the proposed roles of noncoding RNA[J].Breast CancerRes,2015,17(1):40. [3] 宋洋,胡燕萍,王锐.sFas和sFasL在乳腺癌辅助化疗过程中的表达及意义[J].中国生化药物杂志,2016,36(12):183-185. SONG Yang,HU Yanping,WANG Rui.The expression and significance ofsFas and sFasL in adjuvant chemotherapy of breast cancer[J].Chinese Journal of Biochemical Medicine 2016,36(12):183-185. [4] MASOOD S.Neoadjuvant chemotherapy in breast ca-ncers[J].Womens Health(Lond),2016,12(5):480-491. [5] 杨伟斌,刘志毅,曹宽,等.表皮生长因子受体家族特点及与肿瘤关系的研究进展[J].现代肿瘤医学,2019,27(2):346-350. YANG Weibin,LIU Zhiyi,CAO Kuan,et al.Research progress on the characteristics of epidermal growth factor receptor family and its relationship with tumors[J].Journal Modern Oncology,2019,27(2):346-350. [6] 葛晗,王水.lncRNA对乳腺癌化疗耐药作用研究进展[J].中华肿瘤防治杂志,2017,24(22):1611-1614. GE Han,WANG Shui.Progress of research on the mechanism of IncRNA in chemoresistance of breast cancer[J].Chinese Journal of Cancer Prevention and Treatment,2017,24(22):1611-1614. [7] 张建波,宋魏,王媛媛,等.miR-133通过Notch1信号通路调控BCAR4对乳腺癌迁移和侵袭的影响[J].中国肿瘤生物治疗杂志,2017,24(7):733-741. ZHANG Jianbo,SONG Wei,WANG Yuanyuan,et al.MiR-133 manages effect of BCAR4 on migration and invasion of the breast cancer cells through Notch1 signaling pathway[J].Chinese Journal of Cancer Biotherapy,2017,24(7):733-741. [8] 李秀楠,刘爱蕙,唐欣,等.尿路上皮癌相关1基因通过竞争性抑制miR-18a增强乳腺癌细胞的他莫昔芬治疗耐药性[J].北京大学学报(医学版),2017,49(2):295-302. LI Xiunan,LIU Aihui,TANG Xin,et al.Urothelial carcinoma-associated 1 enhances tamoxifen resistance in breast cancer cells through competitivelyinhibiting microRNA-18a[J].Journal of Peking University(Health Sciences),2017,49(2):295-302. [9] LIU Hongying,WANG Gang,YANG Lili,et al.Kno-ckdown of long non-coding RNA UCA1 increases the tamoxifen sensitivity of breast cancer cells through inhibition of wnt/β-catenin pathway[J].PLoS One,2016,11(12):e0168406. [10] 赵义,张行行,徐岷.长非编码RNA UCA1在肿瘤中的表达及作用[J].国际肿瘤学杂志,2015,42(7):519-521. ZHAO Yi,ZHANG Xingxing,XU Min.Expressions and roles of long non-codingRNA UCA1 in tumors[J].International Journal of Oncology,2015,42(7):519-521. [11] 李娜,赵晓娟,苏晓明.乳腺组织中SMG-1mRNA和SOX4mRNA检测在乳腺癌监测中的应用[J].现代检验医学杂志,2019,34(2):35-39. LI Na,ZHAO Xiaojuan,SU Xiaoming.Application of detection of SMG-1 mRNAand SOX4 mRNA in breast tissues in surveillance for breast cancer[J].Journalof Modern Laboratory Medicine,2019,34(2):35-39.

相似文献/References:

[1]党小军,张华,王欣.人附睾蛋白4(HE4)在乳腺癌诊断中的价值[J].现代检验医学杂志,2015,30(06):84.[doi:10.3969/j.issn.1671-7414.2015.06.024]
　DANG Xiao-jun,ZHANG Hua,WANG Xin.Value of Human Epididymis Protein 4(HE4) in Diagnosis of Breast Cancer[J].Journal of Modern Laboratory Medicine,2015,30(05):84.[doi:10.3969/j.issn.1671-7414.2015.06.024]
[2]张 萍,任世云,张 雷.乳腺癌患者血清脂质运载蛋白-2 和基质金属蛋白酶-9的表达及临床意义[J].现代检验医学杂志,2015,30(01):72.[doi:10.3969/j.issn.1671-7414.2015.01.019]
　ZHANG Ping,REN Shi-yun,ZHANG Lei.Expression and Clinical Significance of Serum LCN-2 and MMP-9 in Patients with Breast Cancer[J].Journal of Modern Laboratory Medicine,2015,30(05):72.[doi:10.3969/j.issn.1671-7414.2015.01.019]
[3]乔雪峰a,黄志平b,张 宁c,等.IL-18基因启动子区-137G/C,-607G/T 2个位点基因多态性与女性乳腺癌易感性Meta分析[J].现代检验医学杂志,2016,31(04):65.[doi:10.3969/j.issn.16717-414.2016.04.017]
　QIAO Xue-fenga,HUANG Zhi-pingb,ZHANG Ningc,et al.Association Analysis of IL-18 Gene Promoter Region -137G/C,-607G/T Polymorphisms and Susceptibility to Sporadic Breast Cancer:Meta-Analysis[J].Journal of Modern Laboratory Medicine,2016,31(05):65.[doi:10.3969/j.issn.16717-414.2016.04.017]
[4]刘延梅,马少君,张月浪,等.人类表皮生长因子受体2在乳腺癌表达与临床的相关病理特征分析[J].现代检验医学杂志,2016,31(05):91.[doi:10.3969/j.issn.1671-7414.2016.05.024]
　LIU Yan-mei,MA Shao-jun,ZHANG Yue-lang,et al.Expression of Human Epidermal Growth Factor Receptor 2 and Correlation with Clinical Pathological Features in Breast Cancer[J].Journal of Modern Laboratory Medicine,2016,31(05):91.[doi:10.3969/j.issn.1671-7414.2016.05.024]
[5]陈雨欣,谭婷婷,宁明哲.乳腺癌患者血清中白介素35(IL-35)的表达及其临床意义[J].现代检验医学杂志,2017,32(02):92.[doi:10.3969/j.issn.1671-7414.2017.02.025]
　CHEN Yu-xin,TAN Ting-ting,NING Ming-zhe.Serological Interleukin-35 Level in Patients with Breast Cancer and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2017,32(05):92.[doi:10.3969/j.issn.1671-7414.2017.02.025]
[6]唐努尔·艾尔肯,阿孜古·祖农.盐酸罗哌卡因对人乳腺癌细胞运动作用的研究[J].现代检验医学杂志,2017,32(03):128.[doi:10.3969/j.issn.1671-7414.2017.03.035]
　TANGNUER·Aierken,AZIGU·Zunong.Study on Effect of Ropivacaine on Migration of Breast Cancer Cell s[J].Journal of Modern Laboratory Medicine,2017,32(05):128.[doi:10.3969/j.issn.1671-7414.2017.03.035]
[7]靳庆娥,苏建荣.北京地区汉族女性人群SYK基因启动子区-803A>Trs290987单核苷酸多态性与乳腺癌易感性分析[J].现代检验医学杂志,2018,33(02):5.[doi:10.3969/j.issn.1671-7414.2018.02.001]
　JIN Qing-e,SU Jian-rong.Associations of SYK Promoter-803A >T(rs290987)Single Nucleotide Polymorphisms with Susceptibility to Breast Cancer of Han Female Population in Beijing Area[J].Journal of Modern Laboratory Medicine,2018,33(05):5.[doi:10.3969/j.issn.1671-7414.2018.02.001]
[8]高 华a,李玉柱b,韩龙才c,等.Logistic回归和ROC工作曲线评价联合检测血清CA153,TPS,CYFRA21-1在乳腺癌诊断中的临床价值[J].现代检验医学杂志,2018,33(03):60.[doi:10.3969/j.issn.1671-7414.2018.03.016]
　GAO Huaa,LI Yu-zhub,HAN Long-caic,et al.Clinical Value of Logistic Regression and ROC Work Curve Evaluating Serum CA153,TPS and Cyfra21-1 for Diagnosis of Breast Cancer[J].Journal of Modern Laboratory Medicine,2018,33(05):60.[doi:10.3969/j.issn.1671-7414.2018.03.016]
[9]李 娜a,赵晓娟b,苏晓明a.乳腺组织中SMG-1mRNA和SOX4mRNA检测在乳腺癌监测中的应用[J].现代检验医学杂志,2019,34(02):35.[doi:10.3969/j.issn.1671-7414.2019.02.010]
　LI Naa,ZHAO Xiao-juanb,SU Xiao-minga.Application of Detection of SMG-1mRNA and SOX4mRNAin Breast Tissue in Surveillance for Breast Cancer[J].Journal of Modern Laboratory Medicine,2019,34(05):35.[doi:10.3969/j.issn.1671-7414.2019.02.010]
[10]王承霞,朱玉蓉.乳腺癌患者血清中 tRF-32-Q99P9P9NH57SJ的表达及临床意义[J].现代检验医学杂志,2019,34(06):16.[doi:10.3969 ／ j.issn.1671-7414.2019.06.004]
　WANG Cheng-xia,ZHU Yu-rong.Expression and Clinical Significance of tRF-32-Q99P9P9NH57SJ in Serum of Patients with Breast Cancer[J].Journal of Modern Laboratory Medicine,2019,34(05):16.[doi:10.3969 ／ j.issn.1671-7414.2019.06.004]

备注/Memo

备注/Memo:
作者简介:王 碧(1984-),女,大学本科,主管检验师,研究方向:乳腺癌的基因诊断,E-mail:3432936789@qq.com。 通讯作者:吉茂礼(1982-),男,大学本科,主管检验师,研究方向:肿瘤的基因诊断,E-mail:3435077084@qq.com。
更新日期/Last Update: 2019-10-20